Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Katherine Riccione; Carter M. Suryadevara; David Snyder; Xiuyu Cui; John H. Sampson; Luis Sanchez-Perez

doi:10.3791/52397

Journal

/

Immunology and Infection

/

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

JoVE Journal
Immunology and Infection

A subscription to JoVE is required to view this content. Sign in or start your free trial.

JoVE Journal Immunology and Infection

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

21,302 Views

•

12:55 min

•

February 16, 2015

DOI:

10.3791/52397-v

DOI:

10.3791/52397-v

•

12:55 min

February 16, 2015

•

7 Views

Katherine Riccione^1,2, Carter M. Suryadevara^1,3, David Snyder¹, Xiuyu Cui¹, John H. Sampson^1,2,3, Luis Sanchez-Perez¹

¹Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery,Duke University, ²Department of Biomedical Engineering,Duke University, ³Department of Pathology,Duke University

Summary

The lymphodepletive and immunomodulatory effects of chemotherapy and radiation standard of care can be leveraged to enhance the antitumor efficacy of T cell immunotherapy. We outline a method for generating EGFRvIII-specific chimeric antigen receptor (CAR) T cells and administering them in the context of glioblastoma standard of care.